All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Medicure
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 05, 2020
Details:
The Agreement grants an exclusive right to Medicure to market and sell the Product in the United States of America, Canada and the European Union.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Coenzyme Q10
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Ubiquinol
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2020
Details:
Ubiquinol (the active form of CoQ10) significantly improved FMD in both treated groups compared with the placebo group (Ubiquinol 200 mg/day; Ubiquinol 100 mg/day; placebo).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Everolimus
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ESPRIT BTK
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 03, 2020
Details:
This is the first Investigational Device Exemption (IDE) trial in the U.S. to evaluate a fully resorbable device to treat blocked arteries below the knees, or critical limb ischemia (CLI), in people battling advanced stages of peripheral artery disease (PAD).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PMC-403
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PMC-403
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: NIH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 18, 2020
Details:
Under this agreement, Kirk M. Druey, M.D., and colleagues at the NIAID will investigate PMC-403 in preclinical models. PharmAbcine will discuss potential clinical development in collaboration with the NIH as the study progresses.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Autonomic regulation therapy
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Vitaria
Highest Development Status: Undisclosed Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 12, 2020
Details:
LivaNova will present a poster at the European Society of Cardiology (ESC) Congress 2020 on the potential for autonomic regulation therapy (ART) via vagus nerve stimulation to improve long-term cardiovascular function in patients with heart failure.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sirolimus
Therapeutic Area: Cardiology/Vascular Diseases Product Name: BuMA Suprem
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2020
Details:
SINOMED completed 1-year follow-up in the PIONEER-III trial evaluating the BuMA Supreme Drug-Eluting Coronary Stent (DES). BuMA Supreme is Sinomed's second-generation DES with eG Coating, biodegradable polymer and sirolimus drug.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ESI human embryonic stem cells
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ESI hESC
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: AgeX Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 16, 2020
Details:
The agreement is a key step in AgeX’s licensing and collaboration strategy to facilitate industry and academic access to its hESC lines, its PureStem® cell derivation and manufacturing platform, and its UniverCyte™ immunotolerance technology.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Immune globulin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Norton Heart & Vascular Institute in Louisvill
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 28, 2020
Details:
Octapharma USA is donating Octagam® 10% and cutaquig® 16.5%, the company’s intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG), for the study. BioMatrix will be donating patient education, including instruction in subcutaneous injection.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): miRNA-125b
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2020
Details:
The micro-RNA was identified as suitable for further development based on favorable pharmacokinetic results as well as pharmacodynamic data at the molecular level.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Antisense oligonucleotide therapies
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Lipigon
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 23, 2020
Details:
Under this agreement, Lipigon acquires certain antisense drug candidates, which were developed with Secarna's proprietary LNAplusTM platform, including the corresponding patent portfolio.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
